NT5E and adenocarcinoma: The MSTs of OS were 5.8 years (95% CI, 3.6–9.1) for CD73-high adenocarcinomas and NR (95% CI, 11.5–NR) for CD73-low adenocarcinomas; the corresponding MSTs of RFS were 2.2 years (95% CI, 1.1–4.6) and NR (95% CI, 11.0–NR), respectively.